ClinCalc Pro
Menu
Anti-CTLA-4 monoclonal antibody

Tremelimumab (Specialist drug)

Brand names: Imjudo

Adult dose

Dose: Specialist initiation only — refer to BNF/SmPC
Route: IV
Frequency: per protocol

Clinical pearls

  • Hepatocellular carcinoma (with durvalumab); NSCLC
  • Specialist oncology

Contraindications

  • Active autoimmune disease
  • Severe hepatic impairment
  • Pregnancy
  • Hypersensitivity

Side effects

  • Immune-mediated AEs (colitis, hepatitis, pneumonitis, endocrinopathies)
  • Infusion reactions
  • Severe skin reactions

Interactions

  • Live vaccines
  • Systemic corticosteroids

Monitoring

  • TFTs
  • LFTs
  • Cortisol
  • Symptoms

Reference: BNF; NICE TA887; SmPC; https://bnf.nice.org.uk/drugs/tremelimumab-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.